Aspergillus oryzae cytochrome P450 monooxygenase (CYP57B3) is capable of catalyzing hydroxylation of genistein to produce 3 -hydroxygenistein. Because hydroxylated derivatives of genistein, including 3 -hydroxygenistein, exhibit various pharmacological activities, CYP57B3 would potentially be useful as a biocatalyst in the pharmaceutical field. We therefore performed random mutagenesis of CYP57B3 to improve its catalytic activities for genistein. Random mutations were introduced by error-prone PCR into CYP57B3, resulting in construction of a library of mutants. From 2000 mutants, we isolated one with a triple mutation in CYP57B3, resulting in three amino acid substitutions (V138I, S243N and V463F). The altered protein, designated CYP57B3-mut, had a high level of activity for the production of 3 -hydroxygenistein from genistein. In bioconversion reactions, Saccharomyces cerevisiae expressing CYP57B3-mut showed 14-fold higher production of 3 -hydroxygenistein than that of wild-type CYP57B3. In vitro kinetic analysis revealed that K m values of wild-type and CYP57B3-mut were 14.6 × 10 3 ± 2.7 × 10 3 μM and 15.7 ± 1.0 μM, respectively. These results suggest that the affinity of CYP57B3 for genistein could be dramatically improved by the alterations of V138, S243 and V463 in CYP57B3.
INTRODUCTION
Cytochrome P450 enzymes constitute a large superfamily of heme-containing monooxygenases that catalyze hydroxylation reactions on a large variety of substrates such as xenobiotics, steroids, terpenes and alkaloids, and that therefore have important roles in a number of secondary metabolic systems (Ortiz de Montellano 2005) . To date, more than 35 000 genes encoding cytochrome P450 enzymes have been discovered from all kingdoms of life (http://drnelson.uthsc.edu/cytochromeP450.html). In addition to the biological importance of these enzymes, they have great potential as catalysts in biotechnological applications, enabling regiospecific and stereospecific oxidations of various compounds. These specific oxidations are useful in industrial fields because regiospecific oxidation eliminates intermediate steps, such as blocking and deblocking, which are common in conventional chemical synthesis (Schmid et al. 2001) . In addition, formation of a single end product without by-product formation reduces costs associated with downstream purification steps. Furthermore, enantiomeric mixtures (rather than racemic mixtures) are strictly required in some fields, such as the pharmaceutical industry (Gavrilescu and Chisti 2005; Ro et al. 2006) .
The filamentous fungus Aspergillus oryzae, known as koji mold, is one of the most widely used microorganisms for the production of fermented foods. A. oryzae has been used for >1000 years in Japan, for products such as sake (rice wine), rice vinegar, miso (soybean paste) and shoyu (soy sauce). The genome of A. oryzae has been sequenced and is freely available (Machida et al. 2005) . Previously, we identified 155 genes (including 13 putative pseudogenes) in the A. oryzae genome encoding cytochrome P450 enzymes, and cloned 121 full-length cDNAs encoding open reading frames (Nazmul Hussain Nazir, Ichinose and Wariishi 2010) . From these cDNAs, we constructed a functional screening system of A. oryzae P450 enzymes based upon heterologous expression techniques using Saccharomyces cerevisiae. Consequently, we have characterized various novel reactions, such as the hydroxylation of genistein that is catalyzed by CYP57B3 (Nazmul Hussain Nazir, Ichinose and Wariishi 2011) .
Orobol, or 3 -hydroxygenistein, has a number of valuable pharmacological activities, such as enhancement of the sensitivity of human ovarian carcinoma cells to the anticancer drug paclitaxel (Isonishi et al. 2007) , inhibition of HIV1 integrase (Tewtrakul et al. 2007) , inhibition of melanogenesis (Ding et al. 2015) and protection of hepatocytes (Matsuda et al. 2004) , as well as powerful antioxidant activity (Wang et al. 2016) . Isoflavonoids such as 3 -hydroxygenistein can be isolated from natural sources, including fermented products. However, the supply of these compounds is limited, which presents a problem for their practical utilization. A. oryzae CYP57B3 converts genistein to 8-hydroxygenistein, 6-hydroxygenistein and 3 -hydroxygenistein (Nazmul Hussain Nazir, Ichinose and Wariishi 2011) , and has great potential for production of rare, valueadded isoflavonoids from genistein, a major isoflavonoid in plants such as soybean, fava bean and kudzu (Kaufman et al. 1997) . However, improvements to the catalytic efficiency of CYP57B3 are required for it to have practical applications. We have now produced an improvement in the hydroxylation of genistein to 3 -hydroxygenistein by introducing random mutagenesis toward CYP57B3 and construction of a library consisting of 2000 variants. By comparing product accumulation during whole-cell bioconversion reactions, we identified a triple variant of CYP57B3, designated CYP57B3-mut, which resulted in greater production of 3 -hydroxygenistein from genistein than wild-type CYP57B3 (CYP57B3-wt). To better understand the kinetic properties of the wild-type and variant enzymes, we conducted in vitro enzymatic reactions with microsomal proteins prepared from S. cerevisiae expressing CYP57B3. The results demonstrated that the triple variant CYP57B3-mut had greater affinity for genistein than CYP57B3-wt. To the best of our knowledge, this is the first report of random mutagenesis of a fungal P450 enzyme to increase the production of rare, value-added isoflavonoids.
MATERIALS AND METHODS

Chemicals
Genistein was purchased from Cayman Chemical (Ann Arbor, MI, USA). 5-Aminolevulinic acid was purchased from COSMO BIO (Tokyo, Japan). Yeast nitrogen base without amino acid was purchased from Formedium (Hunstanton, UK). Dropout supplement -Leu was purchased from Clontech Laboratories (Mountain View, CA, USA). 3 -Hydroxygenistein was purchased from ChemFaces (Wuhan, China). Custom synthesized oligonucleotide primers were obtained from Hokkaido System Science (Hokkaido, Japan). All other chemicals were of reagent grade. Deionized water was obtained from a Milli-Q R System (Merck Millipore, Darmstadt, Germany).
Construction of a random mutagenesis library
Random mutagenesis of the CYP57B3 gene was carried out by error-prone PCR using a GeneMorph II Random Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The open reading frame of CYP57B3 cloned into the pGYR vector (pGYR-57B3) was generated as previously reported (Nazmul Hussain Nazir, Ichinose and Wariishi 2011 The CYP57B3 sequence in the pGYR vector encodes two additional amino acid residues (threonine and alanine) after the N-terminal methionine; these residues were not counted when referring to residues altered by mutation.
The CYP57B3 
Screening of mutant library and identification of nucleotide substitutions
A 50 μL aliquot of each transformant from the CYP57B3 mutant library was inoculated into a 96-well deep-well plate with 0.5 mL of 4 × synthetic-dextrose medium containing 0.25 mM genistein, 0.2% (v/v) Tween80 and 0.5 mM 5-aminolevulinic acid, and incubated in a Micro Bio Shaker at 28 • C. After incubation for 2 days, reactions were stopped by the addition of 0.5 mL methanol. After removal of cell debris by centrifugation (1300 × g for 10 min) and filtration (PVDF, 0.45 μm pore size, Merck Millipore), metabolic products were analyzed by high-performance liquid chromatography (HPLC 
In vitro reaction using microsomal proteins
Microsomal fractions of S. cerevisiae were prepared as previously described (El-Awaad et al. 2016) , and experimental conditions for microsomal preparation are detailed in the Supplementary Material (Section S2, Supporting Information). The concentration of microsomal proteins was determined using a TaKaRa Bradford Protein Assay Kit (TaKaRa, Kusatsu, Japan). The reaction mixture (100 μL) consisted of 500 μg mL −1 microsomal protein, 1 mM NADPH, 4 μg mL −1 superoxide dismutase and various fixed concentrations of genistein in 100 mM potassium phosphate buffer (pH 7.4) containing 25% (w/v) glycerol. The reaction was initiated by the addition of NADPH, incubated at room temperature and terminated by the addition of 100 μL methanol. Product formation was confirmed by HPLC after removal of cell debris by centrifugation (21 500 × g) and filtration (0.25 μm pore size). Experimental conditions for HPLC analysis were the same as those for analysis of the whole-cell reactions. Michaelis-Menten kinetics was analyzed by non-linear regression using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
RESULTS AND DISCUSSION
Screening of CYP57B3 mutants
In this study, we employed random mutagenesis by errorprone PCR to create variants of CYP57B3 with augmented genistein-hydroxylation activity. Because the relationships between sequence, structure and function of CYP57B3 were obscure, screening of potential variants from a mutant library was chosen as a promising approach. Random mutations were introduced to the coding sequence of CYP57B3, which was then cloned into the pGYR vector and transformed into Saccharomyces cerevisiae for enzyme expression. More than 2000 transformants of S. cerevisiae harboring CYP57B3 mutations were collected in a mutant library. Catalytic conversion of genistein by the S. cerevisiae transformants was comprehensively analyzed. As reported previously (Nazmul Hussain Nazir, Ichinose and Wariishi 2011), recombinant yeast expressing CYP57B3 hydroxylated genistein, with 3 -hydroxygenistein as a major product (see Fig. S1 , Supporting Information). Although most of the mutations resulted in the loss of catalytic activities, we identified a mutant of CYP57B3, designated CYP57B3-mut, in which the formation of 3 -hydroxygenistein was significantly greater than in CYP57B3-wt during whole-cell bioconversion. Sequence analysis revealed that CYP57B3-mut had six nucleotide substitutions, resulting in three amino acid substitutions: V138I, S243N and V463F (see Figs S3 and S4, Supporting Information). As shown in Fig. 1 , accumulation of 3 -hydroxygenistein by the CYP57B3-mut was 14-fold higher than that of CYP57B3-wt after incubation for 48 h. The product concentrations in the medium resulting from CYP57B3-wt and CYP57B3-mut were 0.65 μM and 9.33 μM, respectively. During the incubation, there was no marked difference in cell growth rates between CYP57B3-mut and CYP57B3-wt. These results suggested that the mutations increased the catalytic activities of CYP57B3 for genistein. In addition to 3 -hydroxygenistein, CYP57B3 is known to be capable of producing 6-hydroxygenistein and 8-hydroxygenistein, albeit as minor products. Although it was of great interest to elucidate the regioselectivity of the variant enzymes, quantitative analysis of the minor products was not possible, because of their limited accumulation during the reactions. Although further investigation will be necessary for confirmation, our results suggested that the mutations affected the regioselectivity of CYP57B3 in favor of the production of 3 -hydroxygenistein relative to the minor products. We observed no marked difference in the levels of production of 6-hydroxygenistein and 8-hydroxygenistein between the wild-type and variant CYP57B3 enzymes, whereas formation of 3 -hydroxygenistein was considerably higher with CYP57B3-mut than with the wild-type enzyme (Fig. S5 , Supporting Information). Because genistein is one of the major isoflavonoids found in a number of plants, including soybeans, and because its hydroxylated derivatives exhibit unique properties (Isonishi et al. 2007; Tewtrakul et al. 2007; Ding et al. 2015) , these data could contribute to the use of CYP57B3 in pharmaceutical and agricultural applications. Many researchers have made efforts to improve the level of production of 3 -hydroxygenistein, using various approaches. For example, researchers in the group of Dr Te-Sheng Chang developed a fusion of wild-type CYP57B3 and P450 reductase, as well as a periodic hydrogen peroxide-shocking treatment system (Ding et al. 2015; Wang et al. 2016) , and these developments have enabled effective production of 3 -hydroxygenistein. We have now generated variants of CYP57B3 that perform better than the wild-type enzyme for genistein hydroxylation. The use of these improved variants to produce P450 reductase fusion proteins should enable further enhancement of the industrial production of 3 -hydroxygenistein.
Kinetic analysis of genistein hydroxylation
To verify the enzymatic properties of CYP57B3-mut, we conducted kinetic analysis of genistein hydroxylation. The yeast transformants expressed recombinant CYP57B3 as a membrane protein, enabling in vitro reconstruction of the cytochrome P450 reaction system using microsomal fractions. Figure 2 shows the time course of genistein hydroxylation with CYP57B3 recovered in microsomal fractions. The rate of product formation by CYP57B3-mut was faster than that by CYP57B3-wt. We performed steady-state kinetic analysis by measuring the initial rate of 3 -hydroxygenistein formation. Michaelis-Menten analysis demonstrated a marked difference in K m values of 14.6 × 10 3 ± 2.7 × 10 3 μM for CYP57B3-wt and 15.7 ± 1.0 μM for CYP57B3-mut (Fig. 3) , indicating that the mutations substantially increased the affinity of CYP57B3 for genistein. By contrast, the mutations seemed to have a negative effect on the maximum reaction velocity. Although accurate determination of the levels of CYP57B3 variants in the microsomal fractions was not possible because of low expression, the apparent V max values of CYP57B3-wt and CYP57B3-mut were estimated to be 865.0 ± 125.9 pmol min −1 mg protein −1 and 305.5 ± 4.3 pmol min −1 mg protein −1 , respectively. The K m value for genistein of the wild-type CYP57B3 is most probably above the physiological range, suggesting that the physiological reaction rate is much lower than the V max . By contrast, the K m value of CYP57B3-mut was much lower, so even with a slightly lower V max value, CYP57B3-mut would have a much higher physiological reaction rate than the wild-type enzyme. We analyzed cofactor specificity using the microsomal reaction system coupled with NADPH or NADH (see Fig. S5 , Supporting Information). The accumulation of 3 -hydroxygenistein catalyzed by both CYP57B3-wt and CYP57B3-mut coupled with NADPH as cofactor was three times higher than with NADH, suggesting that the mutations might not change the specificity for electron-transfer proteins. These experiments also demonstrated that the P450 reaction catalyzed by CYP57B3 could be achieved with NADH in the absence of NADPH, suggesting that NADH-dependent electron-transfer proteins, such as cytochrome b5 and its reductase, could be alternatively utilized for the reaction catalyzed by CYP57B3. The possible involvement of alternative electron-transfer systems for several fungal P450s has been described previously (Lamb et al. 1999; Syed et al. 2011; Ichinose and Wariishi 2012; Hatakeyama, Kitaoka and Ichinose 2016) . 
Effects of amino acid substitutions
Our results indicated that small changes in amino acid sequence can dramatically affect the catalytic activities of CYP57B3 for genistein; for instance, CYP57B3-mut contained only three amino acid substitutions (V138I, S243N and V463F). To better understand the relationship between sequence and function, these substitutions were individually incorporated into CYP57B3 variants, in addition to alanine substitutions, resulting in six singlesubstitution variants (V138A, S243A, V463A, V138I, S243N and V463F). Figure 4 shows the effects of these single substitutions on the formation of 3 -hydroxygenistein in whole-cell analysis of mutants. The OD 600 values of the cultures were similar to CYP57B3-wt culture (within a range of 0.9 to 1.0-fold), indicating that the mutations did not affect growth, and suggesting that the differences in product formation could be attributed to the enzymatic activities of each mutant. Conversion of genistein by the triple-substitution mutant CYP57B3-mut resulted in far higher concentrations of 3 -hydroxygenistein than conversion by CYP57B3-wt. However, bioconversion by the different single-substitution mutants resulted in considerable variation in 3 -hydroxygenistein formation. Notably, the V138A substitution resulted in a lower concentration of 3 -hydroxygenistein than was seen with CYP57B3-wt, whereas the V138I substitution resulted in a higher concentration of product than was seen with CYP57B3-mut. The accumulation of 3 -hydroxygenistein by V138I was 100-fold higher than by V138A, suggesting that amino acid residue 138 is very important for the control of substrate recognition by CYP57B3. Single substitutions at residues 243 and 463 also had considerable effects on production of 3 -hydroxygenistein compared with CYP57B3-wt. The kinetic properties of the single-substitution variants were further explored, and the results of in vitro reactions demonstrated that the product formation rate with V138I was dramatically improved compared with CYP57B3-wt (Fig. S6 , Supporting Information). Table 1 summarizes the kinetic parameters of CYP57B3 and its variants for the genistein hydroxylation reaction. The K m values of singlesubstitution variants, apart from V138A, were lower than that of CYP57B3-wt, implying that the amino acid residues at positions 138, 243 and 463 have pivotal roles in substrate recognition by CYP57B3. In addition, a high V max value is likely to have contributed to the high level of product formation seen with the V138I variant. The higher level of catalysis with the V138I enzyme than with the V138I-S243N-V463F CYP57B3-mut enzyme demonstrates a lack of synergy between the amino acid alterations. The mechanisms by which each of these substitutions affects CYP57B3 catalysis are not yet known. Future studies could investigate whether alternative combinations of amino acid substitutions at these three sites could further improve the catalytic activities of CYP57B3. Our results suggest that the three identified substitutions (V138I, S243N and V463F), either individually or in combination, could be important for protein engineering of CYP57B3. As previously described, various P450 enzymes could be candidates for use in the genistein hydroxylation process (Pandey et al. 2011) . Mechanistic understanding of the catalytic properties of these enzymes will be required for optimization of their usefulness in industrial applications. In this study, we identified amino acid residues of CYP57B3 that have important roles in substrate recognition. These findings will help us to better understand sequence-structure-function relationships in P450 enzymes that are responsible for genistein hydroxylation.
CONCLUSIONS
We achieved enhancement of hydroxylation of genistein to produce the isoflavonoid 3 -hydroxygenistein through mutational variation of CYP57B3. In vitro kinetic analysis revealed that the triple-substitution variant CYP57B3-mut had great affinity for genistein that enabled more effective conversion than the precursor CYP57B3-wt enzyme. This study should facilitate advanced applications of CYP57B3 derivatives in agricultural and pharmaceutical fields. 52.7 ± 6.7 56.0 ± 2.0 V463F 63.9 ± 11.8 126.6 ± 8.9
The apparent kinetic parameters were determined using microsomal proteins harboring CYP57B3. The data are represented by the mean ± SD (n = 3). ND; not determined.
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